{"filings":[{"id":1304079,"accession_number":"0001699350-26-000042","cik":1699350,"company_name":"SHOULDER INNOVATIONS, INC.","ticker":"SI","form_type":"8-K","filed_at":"2026-06-26T20:09:38+00:00","items":["5.07"],"status":"ready","headline":"Shoulder Innovations stockholders elect two Class I directors and ratify Deloitte as auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Robert Ball re-elected with 10.6M votes for (4.2M withheld); Andrew Hykes re-elected with 14.8M votes for (1,077 withheld).","Ratification of Deloitte & Touche LLP as independent auditor for FY 2026 approved with 16.4M votes for, 2 against, 8,649 abstentions.","Annual meeting held on June 26, 2026; 16,424,584 shares represented a quorum."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":315428422.3166332,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":68081,"accession_number":"0001699350-26-000033","cik":1699350,"company_name":"SHOULDER INNOVATIONS, INC.","ticker":"SI","form_type":"8-K","filed_at":"2026-05-13T20:08:18+00:00","items":["2.02","9.01"],"status":"ready","headline":"Shoulder Innovations Q1 revenue up 65% to $16.7M, raises FY2026 guidance to $65-68M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $16.7M (+65% YoY); implant systems sold 2,184 (+51%); gross margin 77.7%.","Raised FY2026 net revenue guidance to $65-68M from $62-65M, representing 37-44% YoY growth.","Operating loss $9.0M, net loss $8.4M; adjusted EBITDA loss $7.0M; cash and marketable securities $108.5M.","Full commercial launch of InSet I-135RFX Humeral Stem after FDA clearance for additional fracture indications."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":315428422.3166332,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94800,"accession_number":"0001699350-26-000021","cik":1699350,"company_name":"SHOULDER INNOVATIONS, INC.","ticker":"SI","form_type":"8-K","filed_at":"2026-04-27T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Shoulder Innovations launches InSet I-135RFX Humeral Stem with expanded fracture indications","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Full commercial launch of InSet I-135RFX Humeral Stem after limited market release and FDA 510(k) clearance for fracture indications.","Product now indicated for primary, revision, and fracture total shoulder arthroplasty.","Third addition to I-Series humeral stem line in three years, following InSet 95 (2024) and InSet 70 (2025).","CEO Rob Ball says launch supports full spectrum of shoulder arthroplasty procedures.","Built on InSet lateral-lateral implant philosophy shown to reduce complications and improve range of motion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":315428422.3166332,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94799,"accession_number":"0001699350-26-000016","cik":1699350,"company_name":"SHOULDER INNOVATIONS, INC.","ticker":"SI","form_type":"8-K","filed_at":"2026-04-14T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Shoulder Innovations signs 10-year lease for new 15,200 sq ft HQ in Byron Center, MI","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Lease with Ventura Office Park Lot #8, LLC for a new building with office/warehouse space.","Initial term of 10 years with two 5-year extension options and expansion rights.","Aggregate rent over initial term ~$4.4M; security deposit of $33K and $0.5M construction down payment.","Expected occupancy in Q4 2027 upon issuance of certificate of occupancy.","Company intends to use premises as its corporate headquarters."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":315428422.3166332,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107427,"accession_number":"0001699350-26-000010","cik":1699350,"company_name":"SHOULDER INNOVATIONS, INC.","ticker":"SI","form_type":"8-K","filed_at":"2026-03-10T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"Shoulder Innovations reports Q4 revenue $14.4M (+65%), FY2025 revenue $47.3M (+50%), guides 2026 to $62-65M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue Q4 $14.4M (+65% YoY); FY2025 $47.3M (+50% YoY). Gross margin 76.7% Q4, 76.5% FY.","Net loss Q4 $7.8M, FY $40.4M; Adjusted EBITDA loss Q4 $7.0M, FY $36.1M.","Sold 1,976 implant systems in Q4 (+62%); ended 2025 with 134 core/contender surgeons (+61%).","FY2026 revenue guidance $62-65M (31-37% growth); cash $124.3M at Dec 31, 2025.","Director Michael Carusi not standing for re-election; Drew Hykes appointed to Board."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":315428422.3166332,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107426,"accession_number":"0001699350-26-000003","cik":1699350,"company_name":"SHOULDER INNOVATIONS, INC.","ticker":"SI","form_type":"8-K","filed_at":"2026-03-02T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Shoulder Innovations appoints Drew Hykes to board; Geoff Pardo resigns","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Geoff Pardo resigned as Class I director, effective February 26, 2026; no disagreement with management or board.","Andrew (Drew) Hykes appointed as Class I director and Compensation Committee member, filling the vacancy.","Hykes is President & CEO of Okami Medical; formerly CEO of Inari Medical and VP roles at Medtronic and Sequent Medical.","Hykes brings over 25 years of medtech operating experience; board has determined he is independent.","Resignation and appointment effective February 26, 2026, announced via press release on March 2, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":315428422.3166332,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123772,"accession_number":"0001699350-25-000020","cik":1699350,"company_name":"SHOULDER INNOVATIONS, INC.","ticker":"SI","form_type":"8-K","filed_at":"2025-12-03T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Shoulder Innovations partners with INS to develop micro-robotic platform for shoulder arthroplasty","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Strategic partnership with Interventional Systems (INS) to create a shoulder-specific micro-robotic solution.","Robot will integrate with the ProVoyance platform, aiming to enhance surgical precision and workflow.","Designed as a portable unit targeting ASCs, addressing cost and mobility challenges of robotic surgery.","CEO cites rapid market share gains and IPO capital as enablers for this enabling technology expansion.","INS has a track record of deploying micro-robotics in other U.S. healthcare markets with strategic partners."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":315428422.3166332,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123771,"accession_number":"0001699350-25-000015","cik":1699350,"company_name":"SHOULDER INNOVATIONS, INC.","ticker":"SI","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Shoulder Innovations Q3 revenue up 58% to $11.8M; raises FY25 guidance to $45-46M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $11.8M (+58% YoY); net loss $8.7M vs $4.1M loss in Q3 2024.","Gross margin 76.2%; sold 1,584 implant systems (+53% YoY).","Raises full-year 2025 revenue guidance to $45M-$46M from prior $42M-$44M.","Cash $137M after IPO and convertible notes; FDA clearance for fracture indications.","Adjusted EBITDA loss $7.5M vs $2.9M loss; SG&A $15.1M up 78% YoY on growth investments."],"consensus_eps_estimate":-0.3172,"consensus_eps_actual":-7.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":32901000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":315428422.3166332,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140456,"accession_number":"0001699350-25-000008","cik":1699350,"company_name":"SHOULDER INNOVATIONS, INC.","ticker":"SI","form_type":"8-K","filed_at":"2025-09-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Shoulder Innovations Q2 revenue $11M (+33% YoY); FY2025 guidance $42-44M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 net revenue $11.0M, up 33% YoY; gross margin 76.2% (vs 76.9%).","Net loss $19.2M vs $4.2M loss in Q2 2024, driven by $13.1M fair value charge on warrant liability and purchase option.","FY2025 revenue guidance $42M-$44M, implying ~33-39% growth over FY2024.","Raised $115M total gross proceeds from IPO ($75M) and convertible notes ($40M) in July/Aug 2025.","Appointed Rick Buchholz to board; launched InSet 70 humeral stem product."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":315428422.3166332,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140455,"accession_number":"0001628280-25-037418","cik":1699350,"company_name":"SHOULDER INNOVATIONS, INC.","ticker":"SI","form_type":"8-K","filed_at":"2025-08-04T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Shoulder Innovations adopts post-IPO charter with classified board, exclusive forum clauses","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Authorized common stock set at 730M shares; 20M shares of undesignated preferred stock authorized.","Board divided into three classes with staggered three-year terms; directors removable only for cause.","Stockholder action by written consent eliminated; advance notice required for director nominations and proposals.","Exclusive forum: Delaware Chancery for derivative/breach claims; federal court for Securities Act claims."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":315428422.3166332,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}